Net Loss per Common Share (Tables)

6 Months Ended

Jun. 30, 2024

Earnings Per Share [Abstract]

Anti-Dilutive Effect Excluded from Computation of Diluted Net Loss Per Share Attributable to Common Stockholders

The following potentially dilutive securities have been excluded from the calculation of diluted net loss per common share due to their anti-dilutive effect:

	June 30,
	2024		2023
Stock options outstanding		6,956,497		5,304,271
Non-vested and unsettled restricted stock units		3,053,833		3,803,103
Shares reserved for future issuance		1,578,783		1,475,856
Apexigen replacement warrants		1,003,191		—
Employee stock purchase plan		615,603		644,755
Total		13,207,907		11,227,985